Low-Dose IL-2 Therapy in Refractory SLE: Results from Single Center Phase I/IIa Clinical Trial

被引：0

作者：

Humrich, Jens ^{[1
]}

von Spee-Mayer, Caroline ^{[2
]}

Siegert, Elise ^{[3
]}

Rose, Angelika ^{[2
]}

Bertolo, Martina ^{[4
]}

Enghard, Philipp ^{[5
]}

Hiepe, Falk ^{[6
]}

Alexander, Tobias ^{[3
]}

Feist, Eugen ^{[6
]}

Radbruch, Andreas ^{[7
]}

Burmester, Gerd R. ^{[6
]}

Riemekasten, Gabriela ^{[8
]}

机构：

[1] Univ Hosp Schleswig Holstein, Dept Rheumatol, Campus Lubeck, Lubeck, Germany

[2] Charite, Rheumatol & Clin Immunol, Berlin, Germany

[3] Charite Univ Med Berlin, Rheumatol & Clin Immunol, Berlin, Germany

[4] Charite Univ Med Berlin, Dept Rheumatol, Berlin, Germany

[5] Charite Univ Med Berlin, Dept Nephrol, Berlin, Germany

[6] Charite, Berlin, Germany

[7] Deutsch Rheumaforschungszentrum, Berlin, Germany

[8] Univ Klinikum Schleswig Holstein, Dept Rheumatol, Lubeck, Germany

来源：

ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

13L

引用

页数：3

共 50 条

[1] LOW-DOSE IL-2 THERAPY IN REFRACTORY SLE: RESULTS FROM A SINGLE CENTRE PHASE I/IIA CLINICAL TRIAL
Humrich, Jens Y.
von Spee-Mayer, Caroline
Siegert, Elise
Bertolo, Martina
Abdirama, Dimas
Rose, Angelika
Enghard, Philipp
Hiepe, Falk
Alexander, Tobias
Radbruch, Andreas
Burmester, Gerd-Ruediger
Riemekasten, Gabriela
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : A62 - A63
[2] LOW-DOSE IL-2 THERAPY IN REFRACTORY SLE: INSIGHTS FROM A PHASE I/IIA CLINICAL TRIAL
Humrich, J. Y.
von Spee-Mayer, C.
Siegert, E.
Bertolo, M.
Abdirama, D.
Rose, A.
Enghard, P.
Radbruch, A.
Burmester, G. R.
Riemekasten, G.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : A58 - A58
[3] LOW-DOSE IL-2 THERAPY IN SLE: RESULTS FROM A COMBINED PHASE I/IIA CLINICAL TRIAL
Humrich, J.
Von Spee-Mayer, C.
Siegert, E.
Bertolo, M.
Rose, A.
Abdirama, D.
Enghard, P.
Hiepe, F.
Radbruch, A.
Burmester, G. -R.
Riemekasten, G.
[J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S13 - S13
[4] LOW-DOSE IL-2 THERAPY IN REFRACTORY SLE: EARLY INSIGHTS FROM A PHASE I/IIA CLINICAL TRIAL
Humrich, J. Y.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 34 - 34
[5] Low-dose IL-2 for SLE
Thorley, Jennifer
[J]. LANCET RHEUMATOLOGY, 2019, 1 (03): : E143 - E143
[6] Local low-dose IL-2 therapy
Den Otter, W
Balemans, L
Battermann, JJ
Bernsen, MR
Cadee, JA
Dobrowolski, Z
Everse, LA
Fiszer-Maliszewska, L
Gavhumende, R
De Groot, JW
De Groot, K
Hennink, WE
Hill, FWG
Jurgenliemp-Schulz, I
Klein, WR
Koten, JW
Maas, RA
Steerenberg, P
Stewart, R
Zembala, M
[J]. HEPATO-GASTROENTEROLOGY, 1999, 46 : 1280 - 1286
[7] Mechanisms of action of low-dose IL-2 restoration therapies in SLE
Ballesteros-Tato, Andre
Papillion, Amber
[J]. CURRENT OPINION IN IMMUNOLOGY, 2019, 61 : 39 - 45
[8] Low-dose IL-2 therapy for autoimmune diseases
Collison J.
[J]. Nature Reviews Rheumatology, 2019, 15 (1) : 2 - 2
[9] Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2
Miao, Miao
Li, Yuhui
Huang, Bo
He, Jing
Li, Zhanguo
[J]. DERMATOLOGY AND THERAPY, 2020, 10 (05) : 1181 - 1184
[10] Hypomyopathic Dermatomyositis with Refractory Dermatitis Treated by Low-dose IL-2
Miao Miao
Yuhui Li
Bo Huang
Jing He
Zhanguo Li
[J]. Dermatology and Therapy, 2020, 10 : 1181 - 1184

← 1 2 3 4 5 →